Andrew W. Hahn, MD, highlights safety and tolerability data on lenvatinib/everolimus vs cabozantinib for metastatic ccRCC.
Andrew W. Hahn, MD
Advertisement
Articles by Andrew W. Hahn, MD
Andrew W. Hahn, MD, details phase 2 efficacy findings on lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
3
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
